JOIN US AT THE
IUATLD DR-TB WORKING GROUP
SECOND ANNUAL MEETING

Wednesday, 11 October, 2017
16:00 – 17:30, Minerva I

Expo Guadalajara
Verde Valle, 44550 Guadalajara, Jalisco, Mexico

Discussion topics include:

DR-STAT update on global roll-out of 9-month regimen and new drugs | Vivian Cox

Update on activities of the GDI Triage TF | Agnes Gebhard

DR-TB clinical trials expected to provide results by 2018 | Bob Horsburgh

Next steps for the Working Group | Bob Horsburgh

Sign up to receive RESIST-TB’s monthly newsletter and review of recent literature!
Register your email at http://www.resisttb.org/
Wednesday, 11 October

Workshops
08:00 – 14:00 | Accelerated access to new TB medicines, regimens, and diagnostics: the supply management challenges during transitions | Hall 3

08:00 – 14:00 | Accelerating the uptake of new diagnostics, medicines and regimens to eliminate TB through improved guidance and coordination | Los Arcos

09:00 – 12:00 | Introducing new and repurposed anti-TB agents in the era of increasing antimicrobial resistance under programmatic conditions | Degollado II

11:30 – 17:30 | Pharmacokinetics/pharmacodynamics science to accelerate elimination drug-susceptible and drug-resistant TB (full day session) | Hall 2

11:30 – 17:30 | Programmatic implementation of bedaquiline and delamanid: experiences in drug procurement, technical assistance, clinical management and drug safety monitoring | Hall 8

14:30 – 17:30 | Quantification challenges in times of new TB medicines and regimens: country experiences and speed-course using a digital tool | Minerva II

16:00 – 17:30 | MDR-TB working group meeting | Minerva

Post-graduate courses
08:00 – 14:00 | Update on clinical and programmatic management of multi drug-resistant (MDR) and extensively drug-resistant (XDR) TB | Hall 7

08:00 – 14:00 | Implementing novel drugs and regimens for the treatment of multidrug-resistant TB: a skills-building workshop | Colomos I

08:00 – 11:00 | Psychosocial support groups for drug-resistant TB patients | Degollado I

14:00 – 15:30 | Accelerating the response on drug resistance: TB and the antimicrobial resistant (AMR) agenda | Plenary Hall

16:00 – 17:30 | Addressing challenges of drug-resistant TB | Hall 10

Satellite sessions
07:30 – 08:45 | Ordinary people doing extraordinary work to improve the clinical and programmatic management of DR-TB in South Africa | Hall 6

18:00 – 19:30 | Lancet Respiratory Medicine Symposium on Lung Disease in Resource-limited Settings: Drug-resistant TB and Community Acquired Pneumonia | Plenary Hall

Panel Discussion
10:15 – 11:15 | Do we still need the injection for treating multidrug resistant tuberculosis? | Foro Expo Guadalajara

Short Oral Abstracts
10:30 – 12:00 | At the front line of resistance | Hall 5

Poster Discussion Session
12:45 – 13:45 | MDR-TB: burden and trends | Poster Area

12:45 – 13:45 | Muddying the waters - comorbidities in drug-resistant TB | Poster Area

12:45 – 13:45 | The proof is in the pudding - treatment and outcomes for drug-resistant TB | Poster Area

12:45 – 13:45 | Don't resist! Finding the pattern through sequencing | Poster Area

Saturday, 14 October

Symposia
10:30 – 12:00 | Post-exposure management of households exposed to drug-resistant TB: lessons from the field | Hall 13

14:00 – 15:30 | Nursing interventions for support of patients with multidrug-resistant TB | Hall 3

14:00 – 15:30 | Prospects for elimination of multidrug-resistant TB | Hall 13

Poster discussion sessions
12:45 – 13:45 | You can't treat what you don't diagnose: considerations in MDR-TB diagnosis and molecular epidemiology | Poster Area

12:45 – 13:45 | Challenges to the implementation of drug-resistant TB treatment on the ground | Poster Area

Friday, 13 October

Symposia
10:30 – 12:00 | Preventing a public good from becoming a market failure: sustainability of drug-resistant TB medicines markets and supply chains amidst decentralised financing and procurement | Hall 4

14:00 – 15:30 | The evolving landscape of multidrug-resistant TB (MDR-TB) trials in children | Hall 9

14:00 – 15:30 | Pharmacokinetics and pharmacodynamics drugs used to treat other mycobacterial diseases: more difficult than TB! | Hall 13

Oral Abstract sessions
10:30 – 12:00 | MDR-TB treatment: pharmacovigilance and adverse event outcomes from the field | Hall 13